Abacavir/Lamivudine — Competitive Intelligence Brief

Abacavir/Lamivudine (Abacavir/Lamivudine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleoside reverse transcriptase inhibitor (NRTI). Area: Infectious Disease / Virology.

marketed Nucleoside reverse transcriptase inhibitor (NRTI) HIV reverse transcriptase Infectious Disease / Virology Small molecule

Target snapshot

Abacavir/Lamivudine (Abacavir/Lamivudine) — GlaxoSmithKline. Abacavir and lamivudine are nucleoside reverse transcriptase inhibitors (NRTIs) that block HIV reverse transcriptase, preventing viral replication by inhibiting conversion of viral RNA to DNA.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Abacavir/Lamivudine TARGET	Abacavir/Lamivudine	GlaxoSmithKline	marketed	Nucleoside reverse transcriptase inhibitor (NRTI)	HIV reverse transcriptase
dolutegravir/abacavir/lamivudine	dolutegravir/abacavir/lamivudine	University College Dublin	marketed	Antiretroviral combination (INSTI + NRTIs)	HIV integrase, HIV reverse transcriptase
Lamiduvine (Epivir)	Lamiduvine (Epivir)	Catholic University of the Sacred Heart	marketed	Nucleoside Reverse Transcriptase Inhibitor (NRTI)	HIV reverse transcriptase
Switch to DTG + 3TC	Switch to DTG + 3TC	Hospitales Universitarios Virgen del Rocío	marketed	Antiretroviral combination (INSTI + NRTI)	HIV integrase; HIV reverse transcriptase
AZT+3TC+IDV+RTV	AZT+3TC+IDV+RTV	Hospital Clinic of Barcelona	marketed	Antiretroviral combination therapy (NRTI + PI)	HIV reverse transcriptase; HIV protease
CAR	CAR	ViiV Healthcare	marketed	Antiretroviral combination therapy (INSTI + NNRTI)	HIV integrase and HIV reverse transcriptase
Reyataz + Norvir + Truvada	Reyataz + Norvir + Truvada	ViiV Healthcare	marketed	Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nucleoside reverse transcriptase inhibitor (NRTI) class)

1. French National Agency for Research on AIDS and Viral Hepatitis · 3 drugs in this class
2. Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 2 drugs in this class
3. ViiV Healthcare · 2 drugs in this class
4. Nanfang Hospital, Southern Medical University · 2 drugs in this class
5. Asan Medical Center · 1 drug in this class
6. Dong-A ST Co., Ltd. · 1 drug in this class
7. Bristol-Myers Squibb · 1 drug in this class
8. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · 1 drug in this class
9. Fu-Sheng Wang · 1 drug in this class
10. Avexa · 1 drug in this class